Key Takeaways:

• The U.S. Food and Drug Administration (FDA) issued its third Patient-Focused Drug Development (PFDD) guidance titled, “Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments (COAs),”¹ in October 2025. The document provides a structured approach to integrating patient perspectives into clinical trial endpoints, ensuring that outcome measures are scientifically robust, meaningful to patients, and suitable for regulatory decision-making.
• For biopharma companies, the guidance not only refines regulatory expectations but also opens strategic opportunities for intellectual property (IP) protection around outcome assessment tools, validation data, and digital implementation methods.

In its latest PFDD installment, the FDA offers a detailed roadmap for sponsors seeking to design, adapt, or validate COAs that accurately reflect patients’ lived experiences. The guidance establishes the “fit-for-purpose” standard, requiring sufficient qualitative (patient input) and quantitative (psychometric) evidence to support each measure’s intended use. The FDA also identifies four categories of COAs that may serve as clinical trial endpoints:

• Patient-Reported Outcomes (PROs): Direct patient reports on symptoms or daily function.
• Observer-Reported Outcomes (ObsROs): Reports from caregivers, often used in pediatric or cognitively impaired populations.
• Clinician-Reported Outcomes (ClinROs): Evaluations based on clinical judgment by trained health professionals.
• Performance Outcomes (PerfOs): Objective performance tasks administered under standardized conditions.

The guidance emphasizes a stepwise process that begins with understanding the disease and its meaningful aspects of health (MAHs), identifying patient-prioritized concepts of interest (COIs), and then selecting or developing COAs aligned with those priorities. Sponsors are encouraged to validate COAs through patient engagement, cognitive interviews, and psychometric analysis, demonstrating that resulting scores correspond to meaningful clinical benefit. The FDA also highlights operational considerations such as accessibility, respondent burden, standardization, and mitigation of bias. It urges sponsors to engage early with the agency to discuss COA development and endpoint integration.

This PFDD guidance reflects the FDA’s growing expectation that clinical trial endpoints should measure outcomes that patients themselves consider important. By finalizing its guidance on a patient-centered approach to outcome measurement, the agency aims to increase both the relevance and reliability of clinical data supporting drug approvals.

Beyond compliance, the new framework also presents product sponsors with opportunities to develop new IP assets around proprietary measurement tools, digital analytics, and validated patient experience datasets.

Aligning COA Design with IP Strategy

Sponsors developing new or adapted COAs should consider early patent filings for novel instruments, scoring algorithms, or digital interfaces that provide new or improved ways to quantify patient experience. Claims can encompass “methods of measuring” or “methods of determining improvement” to protect both clinical and technological innovations. For digital COAs, proprietary data capture and AI interpretation methods may also be safeguarded through software patents and cybersecurity trade secrets.

Leveraging Validation Data and Adaptations for Competitive Advantage

While validation datasets themselves may not be patentable, they can set regulatory benchmarks that are difficult for competitors to replicate. Modifications of existing COAs for new populations or therapeutic contexts, such as pediatric or neurological uses, can also be protected through patents covering adaptation processes and new contexts of use. Sponsors should coordinate IP filings with their regulatory strategy and milestones, using provisional and continuation applications to capture emerging findings throughout the validation lifecycle.

For additional information on developing or protecting clinical outcome assessments under the FDA’s PFDD framework and IP strategies, please contact Wilson Sonsini attorneys Eva F. Yin, William Barrett, Daniel E. Orr, or Roshni Ghosh.

---

[1] U.S. Food and Drug Administration, “Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments” (October 2025), available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome.